Pelvic Congestion Syndrome Treatment Market By Treatment Type (Ovarian and Pelvic Vein Embolization, Venous Stenting, Pharmacological and Conservative Management, Surgical Treatments); By Product Type (Embolic Coils, Vascular Plugs, Sclerosants and Liquid Embolics, Catheters, Guidewires, and Access Sheaths, Contrast Agents and Other Procedure Consumables); By End User (Hospital Outpatient Interventional Radiology Departments, Specialty Vascular and Interventional Radiology Centers, Ambulatory Surgery Centers, Gynecology and Chronic Pelvic Pain Clinics); By Geography, Segment Revenue Estimation and Forecast, 2026–2032

Pelvic Congestion Syndrome Treatment Market: Embolization-Led Care, Reimbursement Barriers, and Expanding Clinical Evidence

The Global Pelvic Congestion Syndrome Treatment Market was valued at USD 1.47 billion in 2025 and is projected to reach USD 2.75 billion by 2032, growing at a CAGR of 9.38%, according to Strategic Market Research.

 

The pelvic congestion syndrome treatment market lies at the intersection of women’s health, vascular medicine, and interventional radiology. Market activity is centered on diagnosing and treating venous-origin chronic pelvic pain through ovarian and pelvic vein embolization, selective venous stenting, and related imaging and disposable products. Conventional surgery and long-term pharmacotherapy play smaller roles, as neither represents the primary contemporary treatment pathway.

 

Revenue is generated through physician and facility payments and the use of embolic coils, vascular plugs, sclerosants, catheters, guidewires, access sheaths, contrast agents, and other procedure-specific consumables. Demand depends on the number of patients whose symptoms can be linked to pelvic venous reflux or obstruction and who progress through imaging, conservative treatment, specialist referral, insurance authorization, and intervention.

 

The condition is frequently grouped with pelvic venous disorders, chronic pelvic pain, venous insufficiency, or broader embolization activity. The main U.S. procedure code also covers several unrelated venous indications. A defensible market model must use diagnosis-linked completed procedures rather than applying chronic-pelvic-pain prevalence directly to the broader female population.

 

Clinical Standardization Improves Referral and Coverage Decisions

The Society of Interventional Radiology published practice guidance in April 2026 covering clinical evaluation, diagnostic and pre-procedural imaging, pharmacological management, embolization, venous stenting, complications, and long-term follow-up for women with venous-origin chronic pelvic pain. Hospitals and insurers can use clearer patient-selection criteria to distinguish clinically relevant pelvic venous disease from incidental vein dilation, reducing inappropriate procedures and inconsistent authorization decisions.

A 2025 French multisociety consensus developed 72 proposed opinions and retained 65 after expert evaluation. Participating specialists identified endovascular embolization as the primary treatment after suitable imaging assessment. Greater agreement among radiologists, gynecologists, vascular specialists, and chronic-pain clinicians may reduce referral variation and improve access to interventional treatment. Consensus guidance alone does not establish national procedure growth, but it provides a more consistent basis for diagnosis and treatment.

Clinical terminology also influences product selection. Pelvic congestion syndrome is increasingly evaluated within the broader pelvic venous disorders framework because patients may have ovarian or internal iliac vein reflux, venous obstruction, or both. Interventional radiologists generally use embolization for incompetent or refluxing veins, while venous stents are reserved for selected patients with clinically significant obstruction. Suppliers need products and training programs that support anatomy-specific treatment rather than a uniform device strategy for every pelvic venous presentation.

 

The Patient Funnel Narrows Before Intervention

Chronic pelvic pain creates a large referral population, but pelvic venous disease accounts for only part of that burden. Dilated pelvic veins can occur without symptoms, and patients with venous reflux may also have endometriosis, fibroids, bladder disorders, gastrointestinal disease, pelvic-floor dysfunction, neuropathic pain, or musculoskeletal conditions. Treatment decisions require a credible relationship between symptoms, venous abnormalities, and the exclusion of competing causes.

The healthcare-pathway assessment supporting this report calculated a broad U.S. screening proxy of approximately 3.32 million to 4.98 million women by combining population, chronic-pelvic-pain, and venous-symptom inputs. Patient numbers decline at each stage because of low awareness, uncertain diagnosis, response to conservative treatment, limited specialist imaging, absence of interventional-radiology referral, insurance denial, patient preference, and shortages of experienced pelvic-vein specialists.

Diagnostic capacity can influence procedure volume more directly than the availability of another embolic product. Imperial College Healthcare Private Care introduced specialist vascular transvaginal screening in October 2025 to identify pelvic venous abnormalities earlier. Similar services can shorten the pathway between gynecology or chronic-pain consultation and interventional-radiology assessment, although public data do not show patient throughput or conversion into completed embolization procedures.

 

Embolization Drives Procedure and Consumable Spending

Ovarian and pelvic vein embolization is the dominant contemporary treatment for reflux-driven pelvic venous disease. A 2024 systematic review covering 25 studies and 2,038 patients reported technical success of 94% and an overall complication rate of 9.0%. Most studies recorded symptom improvement, although patient-selection methods, treated vessels, embolic materials, clinical endpoints, and follow-up periods varied considerably.

Interventional-radiology departments generally perform embolization as an outpatient or day-case procedure. Public hospital pathways describe treatment with coils and sclerosant foam without routine inpatient admission. Hospitals can therefore add pelvic-vein embolization to established vascular-intervention services without building a separate surgical program, provided they have appropriate imaging, trained physicians, nursing support, authorization processes, and post-procedure follow-up.

Each procedure generates demand for detachable or pushable coils, vascular plugs, foam or liquid sclerosants, diagnostic and microcatheters, guidewires, access sheaths, and contrast products. The number and value of products used vary according to vessel diameter, laterality, collateral anatomy, the number of venous territories treated, and the operator’s preferred embolization strategy. Patients with clinically significant venous obstruction may also require separate diagnostic work and stent placement.

Procedure growth will not automatically produce equal growth in coil units. One study comparing proximal coil occlusion followed by distal sclerotherapy with conventional embolization reported average coil lengths of 19.8 cm and 31.7 cm, respectively. Hospitals paid under bundled procedure arrangements have strong incentives to reduce coil consumption, fluoroscopy exposure, procedure time, and inventory complexity. Suppliers can protect pricing by improving packing efficiency, repositionability, deployment accuracy, and total case economics.

 

Conservative Therapy Delays or Qualifies Patients for Intervention

Analgesics, hormonal suppression, compression therapy, pelvic-floor rehabilitation, and multidisciplinary pain management remain common before intervention. These treatments may provide temporary symptom relief, postpone embolization, or satisfy insurer requirements that conservative management be attempted first.

Public evidence does not identify a PCS-specific branded pharmaceutical category with dedicated prescription volumes or recurring disease-specific revenue. General pain medication, contraceptives, progestins, gonadotropin-releasing hormone agonists, and venotonic products are used across much larger gynecology, pain, and vascular indications. Including all such prescriptions in the pelvic congestion syndrome market would overstate pharmaceutical demand.

Imaging, venography, embolization, and selected stenting generate the largest identifiable revenue per treated patient. Conservative therapy mainly affects when patients become eligible for intervention. Aetna, for example, requires suitable diagnostic evidence and failed pharmacotherapy before considering ovarian or gonadal vein embolization medically necessary.

 

Payer Policy Controls Procedure Conversion

CPT 37241 provides a recognized U.S. billing route for venous embolization, but the code also covers other nonhemorrhagic venous conditions. National totals based solely on CPT 37241 would include venous malformations, varices, varicoceles, and other indications unrelated to pelvic congestion syndrome. Accurate utilization analysis requires diagnosis linkage, provider specialty, treatment setting, and patient-level identification of repeat procedures.

Insurer policies vary substantially. Aetna recognizes ovarian or gonadal vein embolization when imaging and conservative-treatment requirements are satisfied. UMR’s policy effective March 1, 2026, classifies ovarian or internal iliac vein embolization as unproven and not medically necessary. Blue Cross NC similarly considers embolization, ablation, or sclerotherapy of the ovarian and internal iliac veins investigational for pelvic congestion syndrome.

Conflicting coverage policies lead to authorization delays, clinical documentation requirements, appeals, self-pay leakage, and uneven investment in dedicated pelvic-vein services. Hospitals are less likely to build referral programs when reimbursement depends heavily on the patient’s insurance plan. Strong comparative evidence capable of changing medical policies would expand realizable demand more effectively than another product launch within the existing embolization category.

 

Randomized Evidence Will Shape Wider Coverage

The EMBOLIZE trial is the most commercially relevant current evidence initiative. The Society of Interventional Radiology Foundation and VIVA Foundation are sponsoring the prospective randomized controlled study with support from Penumbra. Investigators are examining whether ovarian and pelvic vein embolization reduces chronic pain associated with pelvic venous disease.

Trial sponsors have directly connected the study with the need for stronger evidence supporting insurance coverage. Positive results could improve physician confidence, support more consistent patient-selection criteria, and encourage hospitals to establish dedicated referral and treatment programs. Inconclusive results would reinforce insurer concerns and keep procedure growth concentrated in specialist centers treating carefully selected patients.

Researchers are also examining reproductive outcomes that may affect treatment acceptance among younger women. A 2025 retrospective study of 81 patients reported symptom improvement after endovenous embolization and a statistically significant reduction in anti-Müllerian hormone levels during follow-up. The investigators advised against drawing firm conclusions about ovarian reserve without larger studies. A separate study registered in 2026 is evaluating ovarian function following ovarian-vein embolization.

 

Suppliers Compete on Complete Embolization Workflows

Penumbra has developed one of the clearest PCS-specific positions among embolization suppliers. Its POD, Ruby, and Packing Coil platforms appear in ovarian and pelvic-vein treatment cases, and the company supports the EMBOLIZE randomized trial. Clinical education, large-volume coil options, direct pelvic-vein case visibility, and evidence generation give Penumbra a stronger presence in the treatment pathway than suppliers relying only on a general peripheral-embolization portfolio.

Boston Scientific competes through the EMBOLD Detachable Coil System and the established Interlock and IDC coil families. EMBOLD received FDA clearance in 2022 for peripheral arterial and venous embolization and includes fully retractable coil designs intended to simplify deployment. Hospitals evaluating the portfolio can also access coding and reimbursement support from the company. Public financial disclosures do not separate pelvic congestion syndrome revenue from broader embolization sales.

Terumo expanded its AZUR hydrogel platform with the U.S. launch of the AZUR HydroPack Peripheral Coil System in December 2023. The system was developed for soft packing through compatible microcatheters, which may support complex peripheral and venous occlusion. Terumo can compete for pelvic-vein cases through portfolio breadth, hydrogel-based filling, and catheter compatibility, although the product was not launched specifically for PCS.

Merit Medical added the Siege Vascular Plug and Bearing nsPVA Express Prefilled Syringe to its embolics portfolio in May 2024. Vascular plugs may be relevant to selected large-vessel occlusion strategies, while particle embolics are less central to conventional ovarian-vein treatment. Merit’s wider portfolio of access products, catheters, plugs, particles, and embolic materials allows hospitals to purchase multiple procedural components from one supplier.

PCS-specific company shares cannot be derived from total peripheral-intervention or embolization revenue. Hospitals and interventional radiologists are more likely to compare vessel-size coverage, deployment control, repositionability, catheter compatibility, procedural efficiency, training support, reimbursement assistance, and product availability. Suppliers that reduce treatment time and inventory burden have stronger positioning than companies offering isolated embolic products without workflow support.

 

North America Leads While Asia-Pacific Expands Fastest

North America accounted for an estimated 42.3% of the market in 2025, supported by established embolization billing, specialist interventional-radiology networks, insurer coverage pathways, SIR treatment guidance, and the EMBOLIZE randomized trial. Coverage differences between insurers continue to limit procedure conversion despite the region’s clinical infrastructure.

Europe held an estimated 31.2% share in 2025. France’s 2025 multisociety consensus and established European outpatient embolization pathways support wider clinical acceptance, although fragmented national reimbursement and limited PCS-specific procedure reporting restrict market visibility.

Asia-Pacific is projected to record the fastest regional growth at an estimated 9.4% CAGR during 2026–2032, as interventional-radiology capacity, pelvic venous imaging, and minimally invasive treatment availability expand across major healthcare markets. The region starts from a smaller revenue base, with adoption constrained by uneven specialist access, reimbursement, and diagnostic recognition. Regional shares and growth rates are Strategic Market Research estimates because audited PCS-specific revenue data are unavailable.

 

Embolization Leads the Treatment Segment

Ovarian and pelvic vein embolization accounts for more than 90% of active interventional treatments performed for pelvic congestion syndrome in modern specialist practice. Surgical ligation, hysterectomy, and vein removal collectively represent less than 5% and are generally reserved for failed embolization or overlapping gynecological conditions. Venous stenting occupies the remaining small, anatomy-specific share among patients with clinically significant obstruction. Medication remains widely used before referral but does not represent a comparable procedure-revenue segment.

 

Mechanical Embolics Hold the Largest Product Share

Coils and vascular plugs account for approximately 76.5% of embolic product utilization in published pelvic-vein procedures. Combined treatment with coils and liquid sclerosants represents around 19.4%, while standalone liquid embolic agents account for nearly 4.0%. Mechanical embolics lead because they provide controlled and durable vessel occlusion across different vein diameters. Combined techniques may gain share as hospitals seek better distal closure, lower coil consumption, shorter procedure times, and reduced disposable costs per case.

 

Interventional Radiology Dominates the End-User Segment

Hospital outpatient interventional-radiology departments hold the largest end-user share because they manage venography, embolization, device selection, and post-procedure monitoring. Interventional radiology represented approximately 84% of the procedural evidence included in the 2024 systematic review, compared with about 12% for vascular surgery. The remaining share involved other or multidisciplinary settings. These figures are an evidence-base proxy rather than audited facility revenue shares, but they confirm where purchasing authority and procedural expertise are concentrated.

 

Market Outlook

Diagnostic criteria, stronger specialist referral networks, outpatient treatment capacity, and payer-relevant evidence are expected to improve patient access to embolization. The 2025 French consensus, 2026 SIR guidance, randomized studies, and specialist imaging investment offer a stronger adoption rationale than individual device launches.

Inconsistent diagnosis, nonspecific procedure coding, fragmented insurance coverage, limited randomized comparisons, and uncertainty around long-term reproductive outcomes will continue to restrict procedure conversion. Revenue also depends heavily on newly treated patients because embolization is generally a one-time intervention rather than a maintenance therapy.

 

Pelvic Congestion Syndrome Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.47 Billion
Revenue Forecast in 2032	USD 2.75 Billion
Overall Growth Rate	CAGR of 9.38% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Product Type, By End User, By Geography
By Treatment Type	Ovarian and Pelvic Vein Embolization, Venous Stenting, Pharmacological and Conservative Management, Surgical Treatments
By Product Type	Embolic Coils, Vascular Plugs, Sclerosants and Liquid Embolics, Catheters, Guidewires, and Access Sheaths, Contrast Agents and Other Procedure Consumables
By End User	Hospital Outpatient Interventional Radiology Departments, Specialty Vascular and Interventional Radiology Centers, Ambulatory Surgery Centers, Gynecology and Chronic Pelvic Pain Clinics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Market Drivers	Growing clinical acceptance of ovarian and pelvic vein embolization Improving diagnostic and referral standardization Expansion of outpatient interventional-radiology capacity
Customization Option	Available upon request